Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Edward Chu's publication output changed over time?
ScholarIQpublication output · 1990–2021
Output grew0% over the shown period — from 1 works in 1990 to 1 in 2021.
1
1
1
1
1
1
1
1
2
1
1990199119931995200720082009201420162021
What are the most-cited papers on Edward Chu?
ScholarIQmost cited works
A History of Cancer Chemotherapy
Vincent T. DeVita, Edward Chu
Cancer Research. 20081,955 CitationsOPEN ACCESS
Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.
Edward Chu, David M. Koeller, John Casey, J C Drake, Bruce A. Chabner, Patrick C. Elwood, S Zinn, Carmen J. Allegra
Proceedings of the National Academy of Sciences. 1991386 CitationsOPEN ACCESS
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Glen J. Weiss, Jasgit C. Sachdev, Manpreet Chadha, Maddie Fulk, Samuel Ejadi, James M. Mountz, Michael T. Lotze, Frederico G. S. Toledo, Edward Chu, Michael Jeffers, Carol E. Peña, Chenjing Xia, Stefanie Reif, Isabelle Genvresse, Ramesh K. Ramanathan
Annals of Oncology. 2016237 CitationsOPEN ACCESS
Therapeutic drug monitoring of 5-fluorouracil
James J. Lee, Jan H. Beumer, Edward Chu
S117498271. 2016226 Citations
Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
Muhammad Wasif Saif, Adrienne Choma, Salvatore J. Salamone, Edward Chu
JNCI Journal of the National Cancer Institute. 2009214 Citations
Related on ScholarIQ
Baptist Hospital of Miami
Institution
A History of Cancer Chemotherapy
Paper
Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.
Paper
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Paper
Therapeutic drug monitoring of 5-fluorouracil
Paper
Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
Paper